Sugar and stroke: Cerebrovascular disease and blood glucose control

Cardiovascular Therapeutics

Volumn 29, Issue 6, 2011, Pages

  Quinn, T J ^a   Dawson, J ^a   Walters, M R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Acute stroke; Diabetes mellitus; Hyperglycemia; Insulin

Indexed keywords

GLUCOSE; INSULIN;

BLOOD CLOT LYSIS; BLOOD GLUCOSE MONITORING; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; EVIDENCE BASED PRACTICE; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANIMALS; BLOOD GLUCOSE; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 82355172783     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00166.x     Document Type: Review

References (134)

1. Centres for Disease Control and Prevention. National Diabetes Fact Sheet: General Informationand National Estimates on Diabetes in the United States. Department of Health and Human Services CfDCAP, editor. Atlanta, GA, 2003.
2. Harris MI. Undiagnosed NIDDM: Clinical and public health issues. Diabetes Care 1993;16:642-652.
3. Hashimoto K, Ikewaki K, Yagi H, et al. Glucose intolerance is common in Japanese patients with acute coronary syndrome who were not previously diagnosed with diabetes. Diabetes Care 2005;28:1182-1186.
4. Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25:1880-1890.
5. Harris M. Daibetes in America: Epidemiology and scope of the problem. Diabetes Care 1998;21(Suppl 3):s11-s14.
6. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
7. Banerjee S, Biram R, Chataway J, Ames D. South Asian strokes: Lessons from the St Mary's stroke database. QJM 2010;103:17-21.
8. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038.
9. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
10. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
11. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-412.
12. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001;322:15-18.
13. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practitioner Project. Diabetologia 1996;39:1540-1545.
14. Feskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular disease: The Zutphen study. J Clin Epidemiol 1992;45:1327-1334.
15. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch Intern Med 2008;168:2070-2080.
16. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies. BMJ 2006;332:73-78.
17. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: A comparison of severity and outcome. Diabetes Care 2001;24:1433-1437.
18. Kjaergaard SC, Hansen HH, Fog L. In-hospital outcome for diabetic patients with acute myocardial infarction in the thrombolytic era. Scand Cardiovasc J 1999;33:166-170.
19. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014-1019.
20. DECODE investigators. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-621.
21. Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K. Diabetes and the risk of stroke. The Honolulu Heart Program. JAMA 1987;257:949-952.
22. Woodward M, Zhang X, Barzi F, et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 2003;26:360-366.
23. Jorgensen H, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes. The Copenhagen Stroke Study. Stroke 1994;25:1977-1984.
24. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: The Whitehall study. Br Med J (Clin Res Ed) 1983;287:867-870.
25. Sung J, Song YM, Ebrahim S, Lawlor DA. Fasting blood glucose and the risk of stroke and myocardial infarction. Circulation 2009;119:812-819.
26. Thammaroj J, Subramaniam V, Bhattacharya JJ. Stroke in Asia. Neuroimaging Clin N Am 2005;15:273-282.
27. Klatsky AL, Friedman GD, Sidney S, Kipp H, Kubo A, Armstrong MA. Risk of hemorrhagic stroke in Asian American ethnic groups. Neuroepidemiology 2005;25:26-31.
28. Gandolfo C, Caponnetto C, Del Sette M, Santoloci D, Loeb C. Risk factors in lacunar syndromes: A case-control study. Acta Neurol Scand 1988;77:22-26.
29. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 1999;22:1077-1083.
30. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch Intern Med 2008;168:2070-2080.
31. Fabris F, Zanocchi M, Bo M, et al. Carotid plaque, aging, and risk factors. A study of 457 subjects. Stroke 1994;25:1133-1140.
32. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12. 4 years. Diabetes Care 1999;22:233-240.
33. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147-2155.
34. Tuomilehto J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke 1996;27:210-215.
35. Prosser J, MacGregor L, Lees KR, Diener HC, Hacke W, Davis S. Predictors of early cardiac morbidity and mortality after ischemic stroke. Stroke 2007;38:2295-2302.
36. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ 1997;314:1303-1306.
37. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154:635-641.
38. Fritz VU, Bilchik T, Levien LJ. Diabetes as risk factor for transient ischaemic attacks as opposed to strokes. Eur J Vasc Surg 1987;1:259-262.
39. Weinberger J, Biscarra V, Weisberg MK, Jacobson JH. Factors contributing to stroke in patients with athersclerotic disease of the great vessels: The role of diabetes. Stroke 1983;14:709-712.
40. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: A scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009;40:2276-2293.
41. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007;369:283-292.
42. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch Intern Med 2008;168:2070-2080.
43. Laws A, Marcus EB, Grove JS, Curb JD. Lipids and lipoproteins as risk factors for coronary heart disease in men with abnormal glucose tolerance: The Honolulu Heart Program. J Intern Med 1993;234:471-478.
44. Shahar E, Chambless LE, Rosamond WD, et al. Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003;34:623-631.
45. Uwaifo GI, Ratner RE. The roles of insulin resistance, hyperinsulinaemia and thiazolidinediones in cardiovascular disease. Am J Med 2003;115(Suppl 8A):s12-s19.
46. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 2002;287:2570-2581.
47. Hurst RT, Lee RW. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: Mechanisms and management. Ann Intern Med 2003;139:824-834.
48. Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 2000;35(1 Pt 2):507-511.
49. White RP, Deane C, Vallance P, Markus HS. Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke 1998;29:467-472.
50. Nazir FS, Alem M, Small M, et al. Blunted response to systemic nitric oxide synthase inhibition in the cerebral circulation of patients with Type 2 diabetes. Diabet Med 2006;23:398-402.
51. Gunarathne A, Patel JV, Kausar S, Gammon B, Hughes EA, Lip GY. Glycemic status underlies increased arterial stiffness and impaired endothelial function in migrant South Asian stroke survivors compared to European Caucasians: Pathophysiological insights from the West Birmingham Stroke Project. Stroke 2009;40:2298-2306.
52. Cosentino F, Battista R, Scuteri A, et al. Impact of fasting glycemia and regional cerebral perfusion in diabetic subjects: A study with technetium-99m-ethyl cysteinate dimer single photon emission computed tomography. Stroke 2009;40:306-308.
53. The Diabetes Control and Complications Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
54. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003;348:2294-2303.
55. Jacobson AM, Musen G, Ryan CM, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007;356:1842-1852.
56. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998;352:854-865.
57. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
58. Hankey GJ, Spiesser J, Hakimi Z, Bego G, Carita P, Gabriel S. Rate, degree, and predictors of recovery from disability following ischemic stroke. Neurology 2007;68:1583-1587.
59. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119:351-357.
60. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
61. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
62. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
63. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-2633.
64. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-1289.
65. Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-873.
66. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial. JAMA 2006;296:2572-2581.
67. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471.
68. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 2007;370:1129-1136.
69. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772.
70. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-1419.
71. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch Intern Med 2008;168:2070-2080.
72. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713.
73. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:1004-1010.
74. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
75. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003;361:2005-2016.
76. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696.
77. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.
78. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.
79. Scott JF, Robinson GM, French JM, O'Connell JE, Alberti KG, Gray CS. Prevalence of admission hyperglycaemia across clinical subtypes of acute stroke. Lancet 1999;353:376-377.
80. Sprafka JM, Virnig BA, Shahar E, McGovern PG. Trends in diabetes prevalence among stroke patients and the effect of diabetes on stroke survival: The Minnesota Heart Survey. Diabet Med 1994;11:678-684.
81. Melamed E. Reactive hyperglycaemia in patients with acute stroke. J Neurol Sci 1976;29:267-275.
82. Quinn TJ, Lees KR. Hyperglycaemia in acute stroke-to treat or not to treat. Cerebrovasc Dis 2009;27(Suppl 1):148-155.
83. Fuentes B, Castillo J, San Jose B, et al. The prognostic value of capillary glucose levels in acute stroke. Stroke 2009;40:562-568.
84. Allport L, Baird T, Butcher K, et al. Frequency and temporal profile of poststroke hyperglycemia using continuous glucose monitoring. Diabetes Care 2006;29:1839-1844.
85. Gray CS, Scott JF, French JM, Alberti KG, O'Connell JE. Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing 2004;33:71-77.
86. Gray CS, Taylor R, French JM, et al. The prognostic value of stress hyperglycaemia and previously unrecognized diabetes in acute stroke. Diabet Med 1987;4:237-240.
87. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009;373:1798-1807.
88. Pulsinelli WA, Waldman S, Rawlinson D, Plum F. Moderate hyperglycemia augments ischemic brain damage: A neuropathologic study in the rat. Neurology 1982;32:1239-1246.
89. Lin B, Ginsberg MD, Busto R. Hyperglycemic exacerbation of neuronal damage following forebrain ischemia: Microglial, astrocytic and endothelial alterations. Acta Neuropathol 1998;96:610-620.
90. de Court, Kleinholz M, Wagner KR, Myers RE. Fatal strokes in hyperglycemic cats. Stroke 1989;20:1707-1715.
91. Baird TA, Parsons MW, Phanh T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 2003;34:2208-2214.
92. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: A systematic overview. Stroke 2001;32:2426-2432.
93. Lavie CJ, Milani RV, Artham SM, Patel DA, Ventura HO. The obesity paradox, weight loss, and coronary disease. Am J Med 2009;122:1106-1114.
94. Barth E, Albuszies G, Baumgart K, et al. Glucose metabolism and catecholamines. Crit Care Med 2007;35(9 Suppl):S508-S518.
95. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation 2006;113:1708-1714.
96. Virley D, Hadingham SJ, Roberts JC, et al. A new primate model of focal stroke: Endothelin-1-induced middle cerebral artery occlusion and reperfusion in the common marmoset. J Cereb Blood Flow Metab 2004;24:24-41.
97. Quast MJ, Wei J, Huang NC. Nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester decreases ischemic damage in reversible focal cerebral ischemia in hyperglycemic rats. Brain Res 1995;677:204-212.
98. Quast MJ, Wei J, Huang NC, et al. Perfusion deficit parallels exacerbation of cerebral ischemia/reperfusion injury in hyperglycemic rats. J Cereb Blood Flow Metab 1997;17:553-559.
99. Anderson RE, Tan WK, Martin HS, Meyer FB. Effects of glucose and PaO2 modulation on cortical intracellular acidosis, NADH redox state, and infarction in the ischemic penumbra. Stroke 1999;30:160-170.
100. Ribo M, Molina C, Montaner J, et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 2005;36:1705-1709.
101. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: A vascular perspective. J Cereb Blood Flow Metab 2007;27:435-451.
102. MacDougall NJJ, Muir KW. Animal models of hyperglycemia and middle cerebral artery occlusion. Int J Stroke 2009;4(Supp 2):14-15.
103. Gisselsson L, Smith ML, Siesjo BK. Hyperglycemia and focal brain ischemia. J Cereb Blood Flow Metab 1999;19:288-297.
104. Ennis SR, Keep RF. Effect of sustained-mild and transient-severe hyperglycemia on ischemia-induced blood-brain barrier opening. J Cereb Blood Flow Metab 2007;27:1573-1582.
105. de Court, Kleinholz M, Holm P, et al. Hemorrhagic infarct conversion in experimental stroke. Ann Emerg Med 1992;21:120-126.
106. Hartell NA, Archer HE, Bailey CJ. Insulin-stimulated endothelial nitric oxide release is calcium independent and mediated via protein kinase B. Biochem Pharmacol 2005;69:781-790.
107. Hamilton MG, Tranmer BI, Auer RN. Insulin reduction of cerebral infarction due to transient focal ischemia. J Neurosurg 1995;82:262-268.
108. Yip PK, He YY, Hsu CY, Garg N, Marangos P, Hogan EL. Effect of plasma glucose on infarct size in focal cerebral ischemia-reperfusion. Neurology 1991;41:899-905.
109. Zhu CZ, Auer RN. Optimal blood glucose levels while using insulin to minimize the size of infarction in focal cerebral ischemia. J Neurosurg 2004;101:664-668.
110. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297.
111. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
112. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J 2005;26:650-661.
113. Van Den BG, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-1367.
114. Van Den BG, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005;64:1348-1353.
115. Van Den BG, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: Benefit versus harm. Diabetes 2006;55:3151-3159.
116. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297.
117. Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002;59:669-674.
118. Els T, Klisch J, Orszagh M, et al. Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: Influence on clinical outcome and infarct size. Cerebrovasc Dis 2002;13:89-94.
119. Jaillard A, Cornu C, Durieux A, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke 1999;30:1326-1332.
120. Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: The PROACT II trial. Neurology 2001;57:1603-1610.
121. Ribo M, Molina C, Montaner J, et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 2005;36:1705-1709.
122. Ribo M, Molina C, Montaner J, et al. Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke 2005;36:1705-1709.
123. Ribo M, Molina CA, Delgado P, et al. Hyperglycemia during ischemia rapidly accelerates brain damage in stroke patients treated with tPA. J Cereb Blood Flow Metab 2007;27:1616-1622.
124. Alvarez-Sabin J, Molina CA, Ribo M, et al. Impact of admission hyperglycemia on stroke outcome after thrombolysis: Risk stratification in relation to time to reperfusion. Stroke 2004;35:2493-2498.
125. Gray CS, Hildreth AJ, Sandercock PA, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: The UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007;6:397-406.
126. Gray CS, Hildreth AJ, Alberti GK, O'Connell JE. Poststroke hyperglycemia: Natural history and immediate management. Stroke 2004;35:122-126.
127. Bruno A, Saha C, Williams LS, Shankar R. IV insulin during acute cerebral infarction in diabetic patients. Neurology 2004;62:1441-1442.
128. Walters MR, Weir CJ, Lees KR. A randomised, controlled pilot study to investigate the potential benefit of intervention with insulin in hyperglycaemic acute ischaemic stroke patients. Cerebrovasc Dis 2006;22:116-122.
129. Bruno A, Kent TA, Coull BM, et al. Treatment of hyperglycemia in ischemic stroke (THIS): A randomized pilot trial. Stroke 2008;39:384-389.
130. Johnston KC, Hall CE, Kissela BM, Bleck TP, Conaway MR. The Glucose in Acute Stroke Patients (GRASP) trial outcome results. Stroke 2009;40:s1.
131. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999;281:1112-1120.
132. Adams HP Jr., del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-1711.
133. The Intercollegiate Working Party for Stroke. National clinical guidelines for stroke. Royal College of Physicians, London; Suffolk, UK: Tavenham Press Ltd, 2000.
134. Thomassen L, Brainin M, Demarin V, Grond M, Toni D, Venables GS. Acute stroke treatment in Europe: A questionnaire-based survey on behalf of the EFNS Task Force on acute neurological stroke care. Eur J Neurol 2003;10:199-204.